GBSciences CannaMed Conference Las Vegas, NV

"On April 20, 2017, the team at GB Sciences held its Drug Discovery Conference in Las Vegas, Nevada. To help our patients, GB Sciences is creating a pipeline for the development of novel medicines based on our own patent-pending formulations of chemicals extracted from the Cannabis plant.  GB Sciences has now filed three provisional patent applications on new therapies that are complex mixtures of compounds derived from cannabis, and it has licensed an additional approved patent through its wholly-owned subsidiary, Growblox Life Sciences, LLC."

John Poss
Chairman & CEO of GB Sciences
CannaMed Conference - Wynn Las Vegas

Dr. Andrea Small-Howard, CSO & Board Member of GB Sciences 
and Partner Danielle Russell, MMJ Production MCC - aka Deliciously Dee

This is my partner Andrea Small-Howard, PHD MBA.  She has been studying cannabinoids and medical cannabis for over 15+ years in working in the biopharmaceutical industry. Andrea, Dr. Drea as I call her, and I have been partnered a little over 3 years.  We met on a consult and have been studying along side her has been a true blessing to me over these years.  Looking very forward to our future, our Edible company - Relax With Happy, formulating treatments and creating medicine with this lovely brilliant woman!  I was so very proud to see her lead the Cannabis Science Expo April 20, 2017 at the Wynn Resort of our home base of Las Vegas. 

*Listed below is a list of disorders our formulations of focus are directed and what we hope to come of these therapies.

"Worldwide Clinical Trials is developing a pre-IND plan and designing pilot studies for evaluating the effectiveness of GB Sciences' proprietary cannabis-based therapeutic" , says CMSO.

Neurological Disorders - first patent application contains cannabis-based complex mixtures designed to treat Parkinson's Disease, Lewy Body Dementia, Huntington's Disease, Dementia and Alzheimer's Disease. Overall, there is a lack of good therapies for these patients.  As people are living longer, the numbers of these underrated patients are increasing.  Fortunately, there is a common mechanism underlying these neurological disorders that our therapies address, and we are eager to continue the development of these medications.

Inflammatory Disorders - second patent application contains cannabis-based complex mixtures for the treatment of a variety of inflammatory disorders, which are increasingly prevalent in our society and add more than $300 billion dollars to the healthcare burden in the US.  Some of these disorders included in our patent application are Osteoarthritis, Rheumatoid arthritis, Chron;s disease, Inflammatory Bowel Disease (IBD), allergic asthma, COPD/asthma in adults, eczema, and dermatitis.  Our therapies are designed to help patents in all of these groups by focusing on commonalities i inflammatory pathways that lead to significant pain and suffering for these patients. 

Cardiovascular Disease - third patent describes the use of our myrcene-containing complex mixtures for the treatment of heart disease.  Heart disease remains the number one cause of death in the US, and there have been no novel formulations on the market for heart disease in almost twenty years in the US, the heart disease market is $316 billion dollars.  Our formulations target the TRPV1 receptor that is protected under the approved patent that we licensed from Makai Biotechnology in December of 2016.

Chronic and Neuropathic Pain - third patent application also addresses patients with chronic and nearpathic pain.  Recently, many patients and their physicians have been expressing their dissatisfaction with currently-available pain medications. Growing public and government concerns regarding opiod abuse, make novel pain treatments a promising field of research and development.  Our novel pain formulations are also substantially free of delta-9 tetrahydrocannabinol (THC), which minimizes their potential for abuse.  Pain represents an estimated health burden of between $560 and $650 billion dollars for chronic pain and between $17 and $20 billion dollars for immunological/neuropathic pain in the US alone.  ""

*this information was directly quoted from the website of GB Sciences - find more information on these patents at 

VP of Operations Kevin Kuethe & John Poss CEO of GB Sciences

"GB Sciences partners wth Universities and Contract Research Organizations (CROs), who bring both expertise and infrastructure at a reasonable cost to our program.  Our end goal is not to take these novel formulations to market ourselves, because we know our limitations.  Our goal is to be the perfect partner to those companies with greater resources and experience in the marketing and distribution of medications worldwide." ( )

Dr. Andrea Small-Howard leading Canna Science Conference
Wynn Las Vegas, NV 

Chairman & CEO John Poss

Chief Science Officer (CSO) - Dr. Andrea Small-Howard 


+ Be sure to check out Deliciously Dee's The Happy Chef Expert Cannabis Cookbook for a behind the scenes on "the Herb" and a breakdown of boiling points and recipes to help you maximize the benefits of this healing plant and learn to cook with cannabis

expert cannabis cookbook

Dr. Andrea Small-Howard 
GB Sciences

And a special thanks to :


for their contributions to make this cookbook extra delicious! 

cannabis cookbook
- 1st Edition -

including album "The Prescription" from hip-hop artist 



SNAPCHAT : d.thc



Popular Posts